Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panorama: MM120 in Generalized Anxiety Disorder
NCT06809595Phase 3Active, not recruiting
- Sponsor
- Definium Therapeutics
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of lysergic acid diethylamide D-tartrate in generalized anxiety disorder (GAD), sponsored by Definium Therapeutics. Started Jan 2025; status: active, not recruiting.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06809595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809595.